Cancer screening is a central component of cancer control in the United States, but its population impact depends on more than the availability of effective tests. Screening can detect cancer at an earlier stage and, for selected diseases, identify precancerous lesions that can be treated before invasive cancer develops. At the same time, screening can produce false-positive and false-negative results, complications, overdiagnosis and overtreatment. This narrative review examines the contemporary U.S. cancer-screening landscape, focusing on breast, cervical, colorectal, lung and prostate cancer screening; disparities in screening uptake; health-system implementation; shared decision-making; emerging technologies; and strategies for improving equitable access. The United States continues to face a substantial cancer burden, with the American Cancer Society estimating more than two million new cancer cases and more than 618,000 cancer deaths in 2025, excluding nonmelanoma skin cancer (American Cancer Society [ACS], 2025). Current evidence-based recommendations differ by cancer type and organization. The U.S. Preventive Services Task Force (USPSTF) recommends biennial mammography for women aged 40–74, colorectal cancer screening beginning at age 45, annual low-dose computed tomography for eligible adults at high risk from smoking, and cervical cancer screening for women aged 21–65 under its current final recommendation; ACS recommendations sometimes differ in starting ages, intervals or available test options (USPSTF, 2024a; USPSTF, 2021a; USPSTF, 2021b; USPSTF, 2018; ACS, 2026). National survey evidence shows that screening remains incomplete and socially patterned. In 2023, 79.8% of eligible women were up to date with breast-cancer screening, 75.8% with cervical screening, and 63.5% with colorectal screening according to CDC analysis using NHIS data and USPSTF-based intervals (Sabatino et al., 2025). Lower screening use was associated with limited healthcare access, financial hardship, lack of a usual source of care, transportation barriers and other social determinants. The review argues that improving U.S. cancer screening requires a complete screening pathway: evidence-based eligibility, accessible testing, high-quality interpretation, timely diagnostic follow-up, treatment, surveillance and continuous quality improvement. Future directions include HPV self-collection, improved risk-based screening, more efficient colorectal testing, better integration of screening into primary care, navigation programs, and careful evaluation of multi-cancer early-detection technologies. Equity should remain a central outcome of screening policy because an effective test cannot produce population benefit when eligible people cannot access it or complete the diagnostic pathway.
Keywords:cancer screening; United States; early detection; breast cancer; cervical cancer; colorectal cancer; lung cancer; prostate cancer; screening disparities